A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects Who Are Asymptomatic At Risk for Developing Alzheimer's Dementia

Trial Profile

A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects Who Are Asymptomatic At Risk for Developing Alzheimer's Dementia

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 17 Dec 2017

At a glance

  • Drugs JNJ 54861911 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms EARLY
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 25 Aug 2017 Planned primary completion date changed from 2 Apr 2023 to 10 Apr 2024.
    • 02 Aug 2017 Planned End Date changed from 18 May 2023 to 10 Apr 2024.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top